Literature DB >> 20697668

Timing of arrival to a tertiary hospital after acute ischaemic stroke - A follow-up survey 5 years later.

Deidre Anne De Silva1, Norazieda Yassin, April J P Toh, Dao Juan Lim, Wan Xin Wong, Fung Peng Woon, Hui Meng Chang.   

Abstract

INTRODUCTION: Intravenous tissue plasminogen activator (tPA) within 3 hours of stroke onset is a licensed proven therapy for ischaemic stroke, with recent trial data showing benefit up to 4.5 hours. We previously published in this journal data of a survey conducted in 2004 showing only 9% of ischaemic stroke patients presenting to the Singapore General Hospital (SGH) arrived within 2 hours of onset. We aimed to determine whether the problem of delayed hospital arrival persists in 2009 and to establish the impact of widening the time window for intravenous tPA to 4.5 hours.
MATERIALS AND METHODS: We prospectively surveyed consecutive ischaemic stroke patients admitted to the SGH from 9th March to 30th April 2009. Patients and/or relatives were interviewed with a standardised form similar to the 2004 survey.
RESULTS: Among the 146 ischaemic stroke patients surveyed (median age 67 years, 59% male, median NIHSS score 2), 6% presented to SGH within 2 hours and 15% within 3.5 hours of onset. Median time from stroke onset to hospital arrival was 1245 minutes (20.75 hours). Pre-hospital consultation was significantly associated with hospital arrival after 2 hours from onset. Main reasons cited for delay were not realising the gravity of symptoms (31%) and not recognising them as stroke (27%).
CONCLUSION: Delayed arrival to SGH following acute ischaemic stroke remains a problem in 2009. This confirms the lack of stroke awareness in Singapore and highlights the need for public stroke education. Furthermore, these data confirm that widening the time window for intravenous tPA treatment to 4.5 hours at SGH will increase its utilisation.

Entities:  

Mesh:

Year:  2010        PMID: 20697668

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  5 in total

1.  Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study.

Authors:  Elyar Sadeghi-Hokmabadi; Mehdi Farhoudi; Aliakbar Taheraghdam; Mazyar Hashemilar; Daryous Savadi-Osguei; Reza Rikhtegar; Kaveh Mehrvar; Ehsan Sharifipour; Parisa Youhanaee; Reshad Mirnour
Journal:  Int J Gen Med       Date:  2016-10-25

Review 2.  If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke?

Authors:  Jeremy N Pulvers; John D G Watson
Journal:  Front Neurol       Date:  2017-11-20       Impact factor: 4.003

3.  Emergency medical services use and its association with acute ischaemic stroke evaluation and treatment in Singapore.

Authors:  Hanzhang Xu; Ying Xian; Fung Peng Woon; Janet Prvu Bettger; Daniel T Laskowitz; Yih Yng Ng; Marcus Eng Hock Ong; David Bruce Matchar; Deidre Anne De Silva
Journal:  Stroke Vasc Neurol       Date:  2020-04-08

4.  Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.

Authors:  Angelos Sharobeam; Brett Jones; Dianne Walton-Sonda; Christian J Lueck
Journal:  J Neurol       Date:  2020-03-21       Impact factor: 4.849

5.  Eligibility assessment for intravenous thrombolytic therapy in acute ischemic stroke patients; evaluating barriers for implementation.

Authors:  Hormoz Ayromlou; Hassan Soleimanpour; Mehdi Farhoudi; Aliakbar Taheraghdam; Elyar Sadeghi Hokmabadi; Rouzbeh Rajaei Ghafouri; Mehdi Najafi Nashali; Ehsan Sharifipour; Somayeh Mostafaei; Davar Altafi
Journal:  Iran Red Crescent Med J       Date:  2014-05-05       Impact factor: 0.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.